HYBRID EVENT: You can participate in person at Paris, France or Virtually from your home or work.

6th Edition of World Congress on Infectious Diseases

June 24-26, 2024 | Paris, France

June 24 -26, 2024 | Paris, France
Infection 2024

Dana Naeem Ashoor

Speaker at Infection Conferences - Dana Naeem Ashoor
Arabian Gulf University, Bahrain
Title : Computational evaluation of monoclonal antibodies neutralization power of SARS-CoV-2 variants


The current globally dominant SARS-CoV-2 variants are showing immune escape caused by genetic variations of SARS-CoV-2 S protein epitopes, affecting the efficiency of COVID-19 antibody-based therapy. Agencies responsible for drug evaluation and regulation such as the FDA and EMA are continuously revising their emergency authorization use of several COVID-19 neutralizing antibodies as they proved to be unlikely effective against new variants especially Omicron descendants. Moreover, pharmaceutical companies are pursuing the development of more potent neutralizing antibodies. Therefore, predicting the effects of these variations on immune escape is important to adapt anti-SARS-CoV-2 monoclonal antibodies therapy. Herein, we describe a computational method to evaluate MAbs neutralizing power. This method is based on comparative binding affinity of the 3D generated models of complex between a SARS-CoV-2 variant spike protein and a neutralizing antibody and previous experimental and clinical observations. To test this method, we evaluate the neutralization power of several classes of MAbs once granted emergency use authorization (EUA), and one that is currently under clinical investigation with the new Omicron’s subvariants Eris (EG.5) and Pirola (BA.2.86) and JN.1. The results showed most of the NAbs have moderate to marked reduction of the neutralization power with the new variant. Only one antibody displayed a substantial increase of the binding energy for EG.5 compared to two antibodies with both Pirola (BA.2.86) and JN.1. This in silico generated data indicates that the new SARS-CoV-2 variant escapes neutralization of most of the available therapeutic NAbs. Furthermore, the data showed new potential therapeutic MAbs combination that could be effective for the treatment countermeasure of the new Omicron’s descendants or potential novel variants. Rapid computational predictions of the neutralizing potential of existing anti-SARS-CoV-2 antibodies is very useful in defining MAbs or MAbs combination that could be used for the effective treatment of the new SARS-CoV-2 potential novel variants. Computational evaluation of monoclonal antibodies neutralization power is a rapid and effective alternative to in vitro studies and can be applied to antibody-based treatment of viral infections.


Dr. Ashoor obtained her PhD in 2015 with excellence in Molecular Medicine from the Arabian Gulf University and an MSc in Medical Biotechnology. She completed an 18 months postdoctoral fellowship at Harvard medical school and Massachusetts General Hospital in Boston, MA. She has more than 20 years’ experience in research and academia as a faculty member of the life science department at the Arabian Gulf University in the field of protein In-silico modeling, engineering, and production. Her research focus on monoclonal antibodies engineering in cancer immunotherapy and recently on the molecular aspects of the pathogenesis of SARS-CoV-2 virus-host proteins interaction.